Genetic Basis for Antipsychotic-Induced Weight Gain

PRESS RELEASE FROM

NEUROPSYCHOPHARMACOLOGY

(http://www.nature.com/npp)

This press release is copyrighted to the journal Neuropsychopharmacology.  Its use is granted only for journalists and news media receiving it directly from the Nature Publishing Group.

PLEASE CITE NEUROPSYCHOPHARMACOLOGY AND THE NEUROPSYCHOPHARMACOLOGY WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO www.nature.com/npp/

Genetic basis for antipsychotic-induced weight gain

Full Text

Abstract 

DOI: 10.1038/npp.2009.235

People with certain variants of the cannabinoid receptor 1 gene (CNR1) are more likely to gain substantial amounts of weight on antipsychotic medications than those without these genetic variants, reports a study online this week in Neuropsychopharmacology. Antipsychotic medications have revolutionized the treatment of schizophrenia, but the associated weight gain experienced by some patients can create health complications and lead to less successful responses to treatment. This research could help identify those at risk.

To investigate a previously theorized link between CNR1 and weight regulation, James Kennedy, Daniel Mueller and colleagues analyzed DNA from 183 patients from mixed ancestries who underwent treatment for chronic schizophrenia. Analyses that controlled for ethnicity revealed an association between CNR1 variants and antipsychotic-induced weight gain for several gene loci.

If these results are replicated in a larger study, CNR1 variants could potentially be used to identify people who are susceptible to antipsychotic-induced weight gain and aid in the development of new schizophrenia medications that avoid this side effect.

Author contacts:

James Kennedy (Center for Addiction and Mental Health, Ontario, Canada)

Tel: +1 416 979 4987; E-mail: James_Kennedy@camh.net

Daniel Müller (Center for Addiction and Mental Health, Ontario, Canada)

Tel: +1 416 979 4987; E-mail: Daniel_Mueller@camh.net

Editorial contact: Diane Drexler (Neuropsychopharmacology, Nashville, TN, USA) Tel: +1 615 324 2371; E-mail: journal@acnp.org
 

Annual Meeting

Program CoverThe ACNP Annual Meeting is one of the world's leading forums for the exchange of cutting edge scientific information about the brain, behavior, and psychotropic drugs.

ACNP Publications

Program CoverThe College offers a variety of Publications with the latest and most comprehensive research in psychopharmacology and related fields.

Research Discussions

This forum enables discussion of articles that have appeared in Neuropsychopharmacology. It is intended to stimulate scholarly interactions among researchers, and to help educate members of the public who are interested in psychiatric illness.